Open AccessSuccessful benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis
Author(s) -
Nabil Belfeki,
Sarra Abroug,
N. Ghriss,
Ibrahim Chouchane,
Sarra Hamrouni,
Alessio Strazzulla,
Souheil Zayet
Publication year - 2021
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/ahyqld
Subject(s) - benralizumab , granulomatosis with polyangiitis , medicine , mepolizumab , eosinophilic , eosinophilia , immunology , monoclonal , eosinophil , vasculitis , asthma , pathology , dermatology , monoclonal antibody , antibody , disease
Eosinophilic granulomatosis with polyangiitis (EGPA) is characterised by many features, including asthma, allergic rhinitis, peripheral and tissue eosinophilia, and vasculitis. Its pathophysiology is still unclear and we suggest that there are different phenotypes of EGPA, which may respond differently to available treatments. Within the most promising targeting biotherapy, benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, has proved both highly effective and safe. We report herewith a case of EGPA presenting a myocarditis relapse successfully treated with benralizumab.